| 1 |
33411110 | Identifying the Dominant Contribution of Human Cytochrome P450 2J2 to the Metabolism of Rivaroxaban, an Oral Anticoagulant. | 2022 Feb |
1 |
| 2 |
34164820 | An insight on the nature of biochemical interactions between glycyrrhizin, myricetin and CYP3A4 isoform. | 2022 Mar |
2 |
| 3 |
34273071 | Perpetrator Characteristics of Azole Antifungal Drugs on Three Oral Factor Xa Inhibitors Administered as a Microdosed Cocktail. | 2022 Jan |
1 |
| 4 |
34856349 | Does the circulating ketoconazole metabolite N-deacetyl ketoconazole contribute to the drug-drug interaction potential of the parent compound? | 2022 Feb 1 |
3 |
| 5 |
35399214 | Characterization of furathiocarb metabolism in in-vitro human liver microsomes and recombinant cytochrome P450 enzymes. | 2022 |
1 |
| 6 |
35439480 | Bulleyaconitine A is a sensitive substrate and competitive inhibitor of CYP3A4: One of the possible explanations for clinical adverse reactions. | 2022 Jun 15 |
1 |
| 7 |
35486324 | A Mechanistic Absorption and Disposition Model of Ritonavir to Predict Exposure and Drug-Drug Interaction Potential of CYP3A4/5 and CYP2D6 Substrates. | 2022 Apr 29 |
1 |
| 8 |
33201347 | Serum 4β-hydroxycholesterol increases during fluconazole treatment. | 2021 May |
1 |
| 9 |
33436520 | Mechanism-Based Inactivation of Cytochrome P450 3A4 by Benzbromarone. | 2021 Apr |
2 |
| 10 |
33440728 | Effect of Microbial Short-Chain Fatty Acids on CYP3A4-Mediated Metabolic Activation of Human Pluripotent Stem Cell-Derived Liver Organoids. | 2021 Jan 11 |
1 |
| 11 |
33568030 | Comparison of the Inhibitory Effects of Clotrimazole and Ketoconazole against Human Carboxylesterase 2. | 2021 |
1 |
| 12 |
33674271 | Metabolic Retroversion of Piperaquine (PQ) via Hepatic Cytochrome P450-Mediated N-Oxidation and Reduction: Not an Important Contributor to the Prolonged Elimination of PQ. | 2021 May |
1 |
| 13 |
33775687 | Roles of CYP3A4, CYP3A5 and CYP2C8 drug-metabolizing enzymes in cellular cytostatic resistance. | 2021 May 1 |
1 |
| 14 |
33826998 | Comparison of the inhibitory effects of azole antifungals on cytochrome P450 3A4 genetic variants. | 2021 Jun |
1 |
| 15 |
33865853 | Elucidation of metabolic pathways of 25-hydroxyvitamin D3 mediated by CYP24A1 and CYP3A using Cyp24a1 knockout rats generated by CRISPR/Cas9 system. | 2021 Jan-Jun |
1 |
| 16 |
34025426 | Integrated Isogenic Human Induced Pluripotent Stem Cell-Based Liver and Heart Microphysiological Systems Predict Unsafe Drug-Drug Interaction. | 2021 |
1 |
| 17 |
34210765 | Differential Reversible and Irreversible Interactions between Benzbromarone and Human Cytochrome P450s 3A4 and 3A5. | 2021 Sep |
1 |
| 18 |
34326139 | Infigratinib Is a Reversible Inhibitor and Mechanism-Based Inactivator of Cytochrome P450 3A4. | 2021 Sep |
1 |
| 19 |
34430783 | In Vitro Model for a Drug Assessment of Cytochrome P450 Family 3 Subfamily A Member 4 Substrates Using Human Induced Pluripotent Stem Cells and Genome Editing Technology. | 2021 Aug |
1 |
| 20 |
34627953 | The detoxification effect of cytochrome P450 3A4 on gelsemine-induced toxicity. | 2021 Dec 15 |
1 |
| 21 |
34648813 | Functional evaluation of vandetanib metabolism by CYP3A4 variants and potential drug interactions in vitro. | 2021 Dec 1 |
1 |
| 22 |
30902024 | Impact of cytochrome P450 variation on meperidine N-demethylation to the neurotoxic metabolite normeperidine. | 2020 Feb |
2 |
| 23 |
31748224 | Piperine Is a Mechanism-Based Inactivator of CYP3A. | 2020 Feb |
1 |
| 24 |
31993325 | Effects of paroxetine, ketoconazole, and rifampin on the metabolism of eliglustat, an oral substrate reduction therapy for Gaucher disease type 1. | 2020 Mar |
1 |
| 25 |
32080863 | Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling. | 2020 Jul |
2 |
| 26 |
32248324 | Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects. | 2020 May |
1 |
| 27 |
32331852 | Versatile applicability of a grid-based CYP3A4 Template to understand the interacting mechanisms with the small-size ligands; part 3 of CYP3A4 Template study. | 2020 Jun |
1 |
| 28 |
32700798 | In vitro and in vivo human metabolism and pharmacokinetics of S- and R-praziquantel. | 2020 Aug |
2 |
| 29 |
29297772 | Assessment of drug-drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of rapamycin kinase. | 2019 Jan |
1 |
| 30 |
30422319 | Pharmacokinetic Interactions of Rolapitant With Cytochrome P450 3A Substrates in Healthy Subjects. | 2019 Apr |
1 |
| 31 |
30783000 | Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions. | 2019 May |
1 |
| 32 |
30828771 | Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs. | 2019 Sep |
1 |
| 33 |
30912163 | Perpetrator effects of ciclosporin (P-glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers. | 2019 Jul |
1 |
| 34 |
30962288 | Modeling of Hepatic Drug Metabolism and Responses in CYP2C19 Poor Metabolizer Using Genetically Manipulated Human iPS cells. | 2019 Jun |
1 |
| 35 |
31028057 | Indinavir Increases Midazolam N-Glucuronidation in Humans: Identification of an Alternate CYP3A Inhibitor Using an In Vitro to In Vivo Approach. | 2019 Jul |
1 |
| 36 |
31089348 | An Investigation into the Role of P-Glycoprotein in the Intestinal Absorption of Repaglinide: Assessed by Everted Gut Sac and Caco-2 Cell Line. | 2019 Winter |
1 |
| 37 |
31089768 | The effect of ketoconazole on praziquantel pharmacokinetics and the role of CYP3A4 in the formation of X-OH-praziquantel and not 4-OH-praziquantel. | 2019 Aug |
1 |
| 38 |
31090092 | Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron. | 2019 Nov |
4 |
| 39 |
31103741 | Human CYP3A4-mediated toxification of the pyrrolizidine alkaloid lasiocarpine. | 2019 Aug |
2 |
| 40 |
31108125 | In silico and in vitro analysis of genetic variants of the equine CYP3A94, CYP3A95 and CYP3A97 isoenzymes. | 2019 Oct |
1 |
| 41 |
31119768 | CYP3A4/5 mediates the metabolic detoxification of humantenmine, a highly toxic alkaloid from Gelsemium elegans Benth. | 2019 Sep |
1 |
| 42 |
31293154 | Characterization of Genetic Variation in CYP3A4 on the Metabolism of Cabozantinib in Vitro. | 2019 Aug 19 |
2 |
| 43 |
31414593 | Tofacitinib Is a Mechanism-Based Inactivator of Cytochrome P450 3A4. | 2019 Sep 16 |
1 |
| 44 |
31456404 | Conformational Response of N-Terminally Truncated Cytochrome P450 3A4 to Ligand Binding in Solution. | 2019 Sep 17 |
1 |
| 45 |
31506301 | Systematic Development and Verification of a Physiologically Based Pharmacokinetic Model of Rivaroxaban. | 2019 Nov |
1 |
| 46 |
28834279 | The Cytochrome P450 Enzyme Responsible for the Production of (Z)-Norendoxifen in vitro. | 2018 Jan |
1 |
| 47 |
29098603 | Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers. | 2018 Apr |
1 |
| 48 |
29102550 | A Physiologically Based Pharmacokinetic Modeling Approach to Predict Drug-Drug Interactions of Buprenorphine After Subcutaneous Administration of CAM2038 With Perpetrators of CYP3A4. | 2018 Mar |
1 |
| 49 |
29129847 | Effects of ketoconazole on cyclophosphamide metabolism: evaluation of CYP3A4 inhibition effect using the in vitro and in vivo models. | 2018 Feb 9 |
2 |
| 50 |
29155491 | Variation in the Response of Clozapine Biotransformation Pathways in Human Hepatic Microsomes to CYP1A2- and CYP3A4-selective Inhibitors. | 2018 Apr |
3 |